SHAREHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
May 25, 2021	Dec. 31, 2021
Repurchase of common stock		$ 394,149
Share repurchase agreement with GSK
Repurchase of common stock (in shares)	32,005,260
Repurchase price per share	$ 12.25
Repurchase of common stock	$ 394,100

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Name:	us-gaap_TreasuryStockValueAcquiredCostMethod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration